Mychoice Cdx
Payments companies reported to CMS as associated with Mychoice Cdx. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Mychoice Cdx, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Mychoice Cdx
These are the largest totals companies reported as associated with Mychoice Cdx. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Thomas Krivak | Pittsburgh, PA | Gynecologic Oncology | $10,802.69 |
| Sharyn Lewin | Teaneck, NJ | Gynecologic Oncology | $7,880.31 |
| Devesh Pandya | Houston, TX | Hematology & Oncology | $4,400.00 |
| Lejla Delic | San Francisco, CA | Gynecologic Oncology | $3,056.18 |
| Antonio Santillan-Gomez | San Antonio, TX | Gynecologic Oncology | $2,916.22 |
| Claire Carman | Norfolk, VA | $1,407.85 | |
| John Chan | San Francisco, CA | Gynecologic Oncology | $862.50 |
| Kirsten Stuber | Tyler, TX | Family | $700.00 |
| Dana Chase | Los Angeles, CA | Gynecologic Oncology | $425.00 |
| Alicia Schollmeyer | Shreveport, LA | Family | $360.70 |
Prescribed Mychoice Cdx?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.